NewEdge Advisors’s ADC Therapeutics ADCT Stock Holding History

NewEdge Advisors’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-36	Closed	-$138	–	3422
2022 Q4	$138	Buy	+36	New	+$144	﹤0.01%	3337

Other funds holding ADCT

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

NewEdge Advisors's ADCT Position: Q1 2023 in Review

NewEdge Advisors sold out of ADC Therapeutics (ADCT) in Q1 2023, closing a stake of 36 shares — an estimated $138 sold.

NewEdge Advisors first reported a position in ADCT in Q4 2022 and held it in 1 quarter. The position peaked at $138 in Q4 2022. 59 funds tracked by Wall St. Rank hold ADCT as of Q1 2023.

NewEdge Advisors reported no remaining ADC Therapeutics position as of Q1 2023 after selling out during the quarter.
NewEdge Advisors sold 36 ADC Therapeutics shares in Q1 2023, an estimated $138.
NewEdge Advisors first reported a position in ADC Therapeutics in Q4 2022 and held it in 1 quarter.
NewEdge Advisors's ADC Therapeutics position peaked at $138 in Q4 2022.
59 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2023.

Based on NewEdge Advisors's 13F filing for Q1 2023, filed 12 May 2023.